Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.60 |
| ▸ | NPY1R | P25929 | 9/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.60 |
| ▸ | NPY2R | P49146 | 5/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | APC | P25054 | 3/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660343 | 0.96 | CTSL (0.64) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL1661018 | 0.96 | CTSL (0.64) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL1663303 | 0.94 | APC (0.61) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL17495215 | 0.91 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL1661910 | 0.90 | CTSL (0.65) | CTSLAPC | |
| SCHEMBL1661176 | 0.90 | CTSL (0.65) | CTSLAPC | |
| SCHEMBL1661922 | 0.90 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL5929274 | 0.89 | CTSL (0.73) | NPY4RNPY1RNPY5RNPY2RCTSL | |
| SCHEMBL1661334 | 0.88 | PTPN1 (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL14509093 | 0.88 | CTSL (0.68) | NPY4RNPY1RNPY5RNPY2RCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | claimed |
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | NPY4R 4859/4885NPY1R 4857/4885NPY5R 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.